A Next Generation Stem Cell Company

Investor Presentation: Cynata Therapeutics Limited

June 2018

Important Information

This presentation has been prepared by Cynata Therapeutics Limited. ("Cynata" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata Therapeutics , nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Investment Summary: a Phase II-ready biotech with a highly scalable, proprietary platform for producing commercial quantities of MSCs

Scalable, globally applicable technology	▪ Cymerus™ platform enables production of high quality Mesenchymal Stem Cells at scale ▪ Fully patented process overcomes multiple issues with today's on-market solutions
Excellent results from Phase I trial in GvHD	▪ All trial endpoints achieved to date: no adverse safety events, highly encouraging efficacy ▪ GvHD programme well positioned to progress to Phase II ▪ Safety data enables Cynata to move directly to Phase II in other indications
Clear pipeline of high-potential target areas	▪ Cardiovascular disease identified as priority indication area for expanded trial pipeline ▪ Planning for Phase II programme in Critical Limb Ischemia (CLI) to commence in H2 2018 ▪ Compelling pre-clinical data in multiple other high-value target areas
Well-funded to progress clinical programme	▪ Pro-forma cash balance of $13.5m based on cash balance of $8.3m as at 31-Mar-18, reinforced by $5.2m placement of shares to leading institutional investor Fidelity International on 30-May-18
Attractive licensing-driven business model	▪ Fujifilm hold licence option for GvHD – will pay all costs of all further development and commercialisation plus $60m in milestone payments plus royalties if exercised ▪ Licence agreements and strategic partners for other indications being explored
Valuable and active market	▪ Estimated $1.7bn revenue opportunity for MSC supplier for GvHD and CLI products alone ▪ Over 850 clinical trials investigating the efficacy of MSCs across numerous indications ▪ Multiple pharma companies active in stem-cell M&A

Cynata has the only platform in the world to produce commercial quantities of Mesenchymal Stem Cells from a single source

Today's on-market MSC manufacturing solution has a number of shortcomings

REGULATORY ISSUES

× Sourcing cells from multiple donors leads to **variability in the sourced cells**, which is a **major regulatory hurdle**

REDUCED EFFICACY

× **Massive cell expansion** is required to create enough cells for therapeutic use, which may **result in reduced efficacy**

Surgery required to source MSCs from bone marrow



Patented Cymerus Platform overcomes shortcomings

✓ **CONSISTENT PRODUCT QUALITY**

Single donor overcomes regulatory concerns

✓ **MAINTAINED PRODUCT EFFICACY**

Cymerus overcomes need for excessive expansion

For more information on the Cymerus platform visit Cynata's website

MSCs are a highly potent form of stem cell attracting significant clinical interest – and in need of a scalable commercial solution

Mesenchymal Stem Cells (MSCs) are believed to play a vital role in repair and regeneration

- ✓ *Modulator of the immune system*
- ✓ *Secrete bioactive molecules and have immunosuppressive and immunoregulatory properties*

Over 850 clinical trials investigating the efficacy of MSCs in treating diseases have been initiated[1]



- ✓ MSCs were approved for use as a therapeutic treatment in Japan in September 2015 and Europe in March 2018

Global commercial potential, with multiple target areas potentially benefiting from MSC treatment



1. www.clinicaltrials.gov (as at June 2018)

Cynata's goal is for its patented Cymerus platform to become the preferred solution for Big Pharma to commercially produce MSCs

Phase I near completion, Phase II planned



GvHD

✓Fujifilm licence option

✓Licence available

Preclinical data



A 'hub and spoke' business model

Intention to license Cymerus across a range of target areas to maximise value

Phase II planned



Critical Limb Ischemia

✓Licence available

Following successful GvHD trial, a new indication will progress direct to Phase II

✓Licence available

Potential future target areas



Trial update | Excellent results in Phase 1 GvHD clinical trial, a clear validation of Cynata's MSCs and the Cymerus platform

Cynata is nearing completion of a **successful Phase 1 clinical trial,** demonstrating **safety** and **meaningful impact on the patients' quality of life**

✓ All endpoints achieved to date

(as at Cohort B 28-day trial update, announced on 21-Jun-18)

	Cohort A (at 28 days)	Cohort A (at 100 days)	Cohort B (at 28 days)
Safety	✓No safety issues / adverse reactions observed		
Complete response *Absence of GvHD*	✓12.5%	✓50%	✓57%
Partial response *Improvement by at least 1 GvHD grade*	✓75%	✓100%	✓86%
Overall survival[1]	✓87.5%	✓87.5%	✓100%

Excellent safety data allows multiple future indications to **progress directly** to Phase II

1. One patient in cohort A died of pneumonia (unrelated to treatment) and one patient in cohort B withdrew from the trial on Day 22 to commence palliative care (but remained alive as at Day 28)

Trial update | Substantial improvement in GvHD grades observed with the majority of patients reporting a Complete Response

Cohort A, lower dose (as at 100-day readout)

Complete Response rate of 50%



Patient #	A1	A2	A3	A4	A5	A6	A7	A8
Grade change	-1	-2	-1	-3	-1	-2	-3	-3
Response level	P	C	P	C	P	P	C	C

Cohort B, higher dose (as at 28-day readout)

Complete Response of 57%



Patient #	B1	B2	B3	B4	B5	B6	B7
Grade change	-2	-3	-3	-2	0	-2	-1
Response level	P	C	C	C	N	C	P

Legend

GvHD grade: As at day 0 | GvHD grade: Best response | C Complete response | P Partial response | N No response

Trial update | Response rate represents a meaningful improvement for a life-threatening, severe disease, in a $300m market opportunity[1]

Trial results to date[2]

Substantial improvement in GvHD grade



GvHD grade scale[3]

Overall GvHD grade based on a combination of skin, liver and gut stages

Stage	Skin stage *% of body surface area affected*	Liver stage *Bilirubin (mg/dl)*	Gut stage *Stool volume (ml/day)*
4	>50% with skin peeling or blistering	≥ 15.0	> 1,500 mL and severe abdominal pain (with or without ileus)
3	>50%	6.0 – 14.9	> 1,500 mL
2	25-50%	3.0 – 5.9	1,000 mL – 1,500 mL
1	<25%	2.0 – 2.9	500 mL – 1,000 mL (or persistent anorexia, nausea and vomiting)
0	0%	< 2.0	≤ 500ml

GvHD is a devastating disease that impacts patients who are already suffering and in need of transplants
*A change in GvHD grade of only 1 has a **meaningful impact on these patients' quality of life***

1. Fujifilm's estimate of the peak annual global sales opportunity (in US$); 2. Represents aggregated results of Cohort A (at 100 days) and Cohort B (at 28 days); 3. Source: www.cibmtr.org

Trial update | Phase 1 GvHD trial was designed to demonstrate safety of Cynata's MSCs and support evaluation of efficacy

What is GvHD?

Graft versus host disease (GVHD) is a condition where following a transplant the donor's immune cells in the transplant (graft) make antibodies against the patient's tissues (host) and attack vital organs. Organs most often affected include the skin, gastrointestinal (GI) tract and the liver.

Overview of GvHD clinical trial

World's first allogeneic iPSC-derived cell therapy clinical trial

Clinical trial protocol	CYP-GvHD-P1-01
Population	~15 adults with steroid-resistant acute GvHD
Clinical sites	7 (UK and Australia)

Endpoints	• Safety and tolerability (primary)
	• Complete/Partial Response by Day 28/Day 100
	  • Complete response = absence of GvHD
	  • Partial response = improvement by at least 1 grade
	• Overall survival at Day 28/Day 100

Current status	• Cohort A – dosing completed Nov 2017, final 100 day readouts completed Feb 2018 • Cohort B – dosing completed May 2018, final 100 day readouts expected in September 2018

Clinical trial design

Screening criteria
- Adults with steroid resistant acute GvHD
- Life expectancy of at least 1 month
- Other conditions screened out that may impact results

Cohort A
May-17 – Dec-17
n=8

$1x10^6$ cells/kg on Day 0 and Day 7[1]

28 day read-out ✓ | 100 day read-out ✓

Data and Safety Monitoring Board (DSMB) assessed Cohort A 28-day data and **approved commencement of Cohort B**

Cohort B
Jan-18 – May-18
n=7[3]

$2x10^6$ cells/kg on Day 0 and Day 7[2]

28 day read-out ✓ | 100 day read-out

1. Max 1x108 cells. 2. Max 2x108 cells 3. One patient withdrew from trial prior to dosing; trial was intended to have 8 participants

Cell therapy is an active market attracting big pharma M&A interest



March 2015

- *Enables Fujifilm to combine technologies with Cellular Dynamics to develop new iPSC based cell therapies*
- *Founder of Cellular Dynamics also founded Cynata*

February 2016

- *Enables Astellas to establish a leading position in cell therapy*
- *Ocata CEO prior to acquisition was Paul Wotton, current Chairman of Cynata*

January 2018[1]

- *Extends existing partnership between Takeda and TiGenix to develop and commercialize Cx601 (darvadstrocel)*
- *TiGenix was the first company to receive approval for an MSC therapy in Europe*

1. Transaction pending completion following acceptance of bid by TiGenix shareholders

Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to maximise shareholder value

Multiple options to create shareholder value

Build value in platform independently
(e.g. continue running clinical trials)

License / partner with big Pharma to develop specific target areas
(e.g. Fujifilm's existing option for GvHD)

Asset sale
(e.g. Strategic acquirer)

Fujifilm holds a licence option for development and commercialisation of Cynata's MSCs for GvHD

Exercise of Fujifilm option (US$3m)

- Fujifilm can exercise up to 90 days after completion of Phase 1 trial.
- On exercise Cynata receive upfront US$3m milestone payment
- Fujifilm responsible for all further development activities and costs

Phase 2 and beyond (US$30m+ p.a.)

- Fujifilm to pay Cynata agreed milestones ($60m+) and double-digit royalties on product sales
- Fujifilm's projections for the GvHD market suggest >US$30m per year in royalties for Cynata

Cynata intends to demonstrate broad global applicability of its Cymerus platform

New enhanced pipeline and clear pathway to commercialisation



1. Fujifilm's estimate of the peak annual global sales opportunity
2. ClearView's estimate of the peak annual global sales opportunity

ClearView were commissioned to evaluate the full landscape of MSC opportunities to identify high priority indications

Indication prioritisation process

ClearView Healthcare Partners

Study commissioned

ClearView identified ~20 high potential target areas with clear scientific and commercial attractiveness

Cardiovascular disease selected by Cynata as highest priority indication area

- ✓ Primary indication: **Critical Limb Ischemia**
- ✓ Progress to clinical trials (direct to Phase II)

Key metrics used to evaluate potential MSC indications

Mechanical / Scientific Attractiveness	• **Expert perspectives and scientific evidence** supporting rationale for use of an MSC approach
Clinical Development Attractiveness	• **Overall burden** (i.e., trial duration, trial size, recruiting hurdles) • **Likelihood of success** (endpoint feasibility) of clinical development
Commercial Attractiveness	• Estimated sales based on **interviews with key opinion leaders** on MSC therapy concepts and accounting for the future competitive landscape

New Phase II programme in Critical Limb Ischemia | Opportunity Overview

cynata therapeutics

Estimated market size

230,000
Addressable events per year

~US$1.4B[1]
Forecast annual global market sales

Critical Limb Ischemia (CLI)	▪ MSC therapy for effective treatment of critical limb ischemia patients who are ineligible for revascularization, to promote angiogenesis and reduce inflammation
Rationale for selection	▪ Cymerus preclinical studies were compelling, animals treated with Cymerus MSCs experienced improved blood flow ($p<0.006$) and faster blood flow recovery ($p<0.001$) when compared to the control group treated with saline ▪ Development timeline is relatively rapid
Preliminary programme design	▪ Pivotal trials may last 1–2 years and require 50–100 revascularisation-ineligible patients (patients not eligible for surgery intended to restore blood flow) ▪ Endpoints likely to include amputation-free survival and ankle-brachial index, ulcer healing, and pain (reviewed over 6–12 months)
Key milestones	▪ Planning for Phase II programme in Critical Limb Ischemia to commence in H2 2018

Critical Limb Ischemia clinical study follows excellent results from an earlier pre-clinical study

cynata therapeutics

Mice dosed with Cymerus MSCs experienced significantly improved outcomes when compared with control group



Animals treated with Cymerus MSCs experienced improved blood flow ($p<0.006$) and faster blood flow recovery ($p<0.001$) when compared to the control group treated with saline

All results published in a peer reviewed journal



Cytotherapy is a peer-reviewed medical journal covering the areas of cell biology and immunology, including cytokines, cytotherapy, and molecular therapy

Cynata is well funded to progress its enhanced clinical pipeline



Cynata is well funded:

- $13.5m pro-forma cash balance[1]
- $6.5m in-the-money stock options[2]
- Cost sharing with licence partners
- R&D expenditure eligible for rebates

1. Cash balance at 31 March 2018 ($8.3m), adjusted for $5.2m cash from 30 May 2018 placement
2. Potential cash inflow if all in-the-money options (as at 21 June 2018) are exercised

Key upcoming milestones



Cynata will continue to progress pre-clinical studies with leading academic and commercial partners

Disease target area		Pre-clinical trials started	Proof of concept completed	Key highlights
Asthma	Monash University	✓	✓	Cymerus MSCs demonstrated significant beneficial effects on three key components of asthma: airway hyper-responsiveness, inflammation and airway remodelling
ARDS	Critical care research group	✓		Study to commence to evaluate effectiveness of Cymerus MSCs in sheep with ARDS in association with the Prince Charles Hospital in Brisbane.
Heart attack	University of Sydney	✓		Pre-clinical trials suggest Cymerus MSCs may have the potential to restore cardiac function and reduce scar size after a heart attack (US$18.2 billion market by 2019[1])
Brain Cancer / Glioblastoma	Harvard/BWH	✓		Research collaboration in genetically modified MSCs in cancer: involves modifying stem cells to target cancer
Diabetic Wounds	CRC for Cell Therapy Manufacturing	✓	✓	Independent study by CRC for Cell Therapy Manufacturing received positive data which demonstrates the efficacy of Cymerus MSCs in a preclinical model of diabetic wounds
Coronary Artery Disease	University of New South Wales	✓		Research collaboration for the development of MSC therapies to treat coronary artery disease

Successful outcomes open many other disease targets potentially benefiting from MSCs

1. http://gbiresearch.com/media-center/press-releases/cardiovascular-disease-market-us-to-lead-modest-growth-forecasts-gbi-research.

Globally experienced board and management team

Dr Paul Wotton
Chairman

Former CEO of Ocata Therapeutics (NASDAQ: OCAT) managing it through a take-over by Astellas Pharma, in a US$379m transaction

Previous executive roles with Antares Pharma Inc. (NASDAQ: ATRS), Topigen Pharmaceuticals and SkyePharma

Founding CEO, Sigilon Therapeutics; member of the boards of Vericel Corporation and Veloxis; past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada

Expertise running and monetising Ocata Therapeutics, acquired by Astellas

Dr Ross Macdonald
Managing Director Chief Executive Officer

30 years' experience and a track record of success in pharmaceutical and biotechnology businesses

Previous senior management positions with Hatchtech, Sinclair Pharmaceuticals, Connetics Corporation (Palo Alto, CA), and Stiefel Laboratories, the largest independent dermatology company in the world and acquired by GSK in 2009 for £2.25b

Track record of success in pharmaceutical and biotechnology businesses

Dr Stewart Washer
Non-Executive Director

20+ years of CEO and Board experience in medical technology, biotech and agrifood companies

Chairman of Orthocell Ltd and Minomic International

Previously CEO roles with Calzada (ASX:CZD), Phylogica (ASX:PYC) and Celentis and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues

Deep experience growing companies as CEO and on the Board

Dr John Chiplin
Non-Executive Director

Significant international experience in the life science and technology industries

Recent transactions include US stem cell company Medistem (acquired by Intrexon), Arana (acquired by Cephalon), and Domantis (acquired by GSK)

Was head of the $300M ITI Life Sciences investment fund in the UK and his own investment vehicle, Newstar Ventures

Overseen and managed a broad range of life sciences transactions

Mr Peter Webse
Non-Executive Director Company Secretary

+25 years' company secretarial experience

Managing Director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services

25+ years company secretarial and management experience

Dr Kilian Kelly
Vice President, Product Development

15 years' experience in pharmaceutical/ biotechnology research and development, in both commercial and academic settings

Previous appointments include Senior Director, Drug Development at Biota Pharmaceuticals (NASDAQ: BOTA), Vice President, Regulatory and Clinical at Mesoblast Limited (ASX:MSB)

Academic and commercial excellence, extensive relevant management experience

Investment Highlights

- **Scalable, world-first technology:** Cymerus platform overcomes inherent challenges of other production methods and enables mass-production of therapeutic MSCs
- **Phase II ready:** Excellent Phase I results provide validation of Cynata's Cymerus platform; Cynata well positioned to progress to Phase II in GvHD and other indications
- **Cardiovascular disease identified as priority indication area for clinical programme:** Planning for Phase II in Critical Limb Ischemia to commence in H2 2018
- **Attractive licensing-driven business model**: Fujifilm licence option for GvHD worth over US$60m plus royalties
- **Valuable market opportunity:** Estimated US$1.7bn revenue opportunity for MSC supplier for GvHD and CLI products alone
- **Well-funded to progress clinical programme:** Pro forma cash balance of $13.5m

Appendix | Key recent newsflow: last 6 months

Release date	Announcement
GvHD	
21-Jun-18	Positive 28-day data from Cohort B
12-Jun-18	Positive 6-month data from Cohort A
24-May-18	Enrolment completed in Cynata's Phase 1 Clinical Trial
28-Mar-18	FDA Grants Orphan Drug Designation to Cynata for CYP-001
27-Feb-18	Excellent 100-day data from Cohort A
24-Jan-18	Cynata treats first patient in Cohort B
22-Jan-18	Encouraging early data – DSMB recommendation to progress to Cohort B
Pre-clinical / other	
18-Jun-18	Research Collaboration with UNSW for Coronary Artery Disease
31-May-18	Cynata's MSCs Effective in Model of Diabetic Wounds
7-May-18	Notice of Allowance from EPO for Cymerus Technology Patent Application
20-Apr-18	CYP completes patent application related to CAR-T Therapy
11-Apr-18	Further US patent granted for Cynata's Cymerus Technology
5-Feb-18	Cynata engineered MSC study interim data review reveals promising results
Commercial	
30-May-18	$5.2m placement of shares to Fidelity International
23-Jan-18	Cynata & Cellularity Inc Execute MOU

Appendix | Corporate overview

Company profile

Cynata Therapeutics is an Australian stock exchange listed clinical-stage biotechnology company developing disruptive regenerative medicines.

Financial information

Share price (21-June-18)	A$1.37
52 week low / high	A$0.54 / A$1.54
Shares on issue[1]	95.1m
Market capitalisation	A$129.8m
Pro-forma Cash (as at 31-March-18)[2]	A$13.5m
Debt (as at 31-March-18)	-
Enterprise value	A$116.3m

Source: IRESS
Notes:
1. *Excludes 11.2m unquoted options with exercise prices ranging from $0.40 to $1.50 and expiry dates between 27-Sep-2018 and 4-Aug-2020 (1m subject to vesting conditions), and 750k unlisted incentive options with exercise price $0.49 and expiring 16 December 2018*
2. *Pro-forma cash calculated as cash balance at 31-Mar-2018 ($8.3m), adjusted for $5.2m cash from 30-May-2018 placement*
3. *Represents shareholding if all options held by the Board and Management (total of 8.55m) are exercised*

Share price performance (last 6 months, A$)



Top shareholders

Shareholder	
Fidelity International	10.0%
Fujifilm Corporation	8.5%
Board and Management	0.6%
Board and Management (fully diluted)[3]	*8.8%*

Thank you for your attention

Cynata Therapeutics Limited
Level 3
62 Lygon Street
Carlton
Victoria 3053
Australia

Contact details:

ross.macdonald@cynata.com

+61 (0) 412 119343

www.cynata.com